Skip to content
F
FinClaro
← All ETFs
XBI

SPDR S&P Biotech ETF

Tracks the S&P Biotechnology Select Industry Index using an equal-weight methodology, tilting toward smaller biotech companies rather than mega-caps. Higher risk/reward profile than market-cap-weighted biotech funds. Sensitive to FDA approvals and clinical trial outcomes.

Backtest X-Ray Correlation Risk Map
EquityTER 0.35%Dist.
TER
0.35%
AUM
$8B
CAGR
11.3%
Volatility
27.0%
Sharpe
0.31
Max Drawdown
-56.7%
Data Range
2006-03 → 2026-04

Performance Analysis

Maximum Drawdown History

How far the ETF has fallen from its all-time high at each point. Deeper = more painful.

Current DD-10.2%
Worst DD-56.7%
Worst date2023-10

Rolling Returns

Annualized returns over rolling windows. Shows the range of outcomes depending on when you invested.

Avg return11.3%
Best44.4%
Worst-17.2%
% positive80%
206 periods

Key Facts

ISIN
US78464A8707
Issuer
State Street
Benchmark
S&P Biotechnology Select Industry Index
Total Expense Ratio (TER)
0.35%
Assets Under Management
$8B approx.
Inception Date
2006-01-31
Domicile
United States
Legal Structure
Open-Ended Fund
Dividend Policy
Distributing (pays dividends)
Replication Method
Physical (Full Replication)
UCITS Status
✗ Not UCITS
Fund Currency
USD
Primary Exchange
NYSE Arca
Number of Holdings
~150

Top 10 Holdings

Top 10 represent 17.7% of the fund.

1
MRNAModerna Inc.
2.20%
2
REGNRegeneron Pharma
2.10%
3
VRTXVertex Pharma
2.00%
4
GILDGilead Sciences
1.90%
5
SGENSeagen Inc.
1.80%
6
ALNYAlnylam Pharma
1.70%
7
BMRNBioMarin Pharma
1.60%
8
EXASExact Sciences
1.50%
9
PCVXVaxcyte Inc.
1.50%
10
IONSIonis Pharma
1.40%
Backtest this ETFOfficial Fund Page

Who Is This ETF For?

✓General portfolio building block for the asset class it covers.

Key Risks to Consider

• Market risk: equity values can drop 30-50% in severe bear markets.

• Non-UCITS: may have unfavorable tax treatment for non-US investors (US estate tax, withholding tax).

Similar ETFs

VTI0.03% TER

Vanguard Total Stock Market ETF

Total US Market · Vanguard

VOO0.03% TER

Vanguard S&P 500 ETF

US Large Cap · Vanguard

QQQ0.20% TER

Invesco QQQ Trust

US Large Cap Tech-Heavy · Invesco

IWM0.19% TER

iShares Russell 2000 ETF

US Small Cap · BlackRock

Continue Your Analysis

Backtest XBI

Compare XBI

X-Ray XBI

Correlation Matrix

Risk vs Return

Check Overlap

Data & Methodology

Metadata sourced from official issuer documentation. Price data from Yahoo Finance (monthly adjusted close, includes reinvested dividends and splits). AUM figures are approximate and updated quarterly.

Data source: Yahoo Finance (adjusted close), State Street (metadata)Last verified: 2026-04-16

Related Guides from FinClaro Chile

How to Invest in S&P 500 from Chile
Compare Chilean, US, and UCITS ETF routes with tax analysis
finclaro.cl
What Is an ETF? Complete Guide
Learn the basics of ETFs, how they work, and why they matter
finclaro.cl
ETF Chile vs International Broker
Compare buying ETFs locally vs through international brokers
finclaro.cl

Related ETFs

Similar ETFs

SPY

SPDR S&P 500 ETF Trust

TER 0.09%$570B AUM
View Compare
VOO

Vanguard S&P 500 ETF

TER 0.03%$560B AUM
View Compare
IVV

iShares Core S&P 500 ETF

TER 0.03%$560B AUM
View Compare
VTI

Vanguard Total Stock Market ETF

TER 0.03%$435B AUM
View Compare

Alternative Approaches

QQQ

Invesco QQQ Trust

TER 0.20%$310B AUM
View Compare
VUG

Vanguard Growth ETF

TER 0.04%$130B AUM
View Compare
VTV

Vanguard Value ETF

TER 0.04%$130B AUM
View Compare
IEFA

iShares Core MSCI EAFE ETF

TER 0.07%$125B AUM
View Compare

💬 Frequently Asked Questions

Tracks the S&P Biotechnology Select Industry Index using an equal-weight methodology, tilting toward smaller biotech companies rather than mega-caps. Higher risk/reward profile than market-cap-weighted biotech funds. Sensitive to FDA approvals and clinical trial outcomes.
XBI has a total expense ratio (TER) of 0.35%, which means you pay $35 per year for every $10,000 invested.
Yes, XBI is a distributing ETF that pays dividends to shareholders. The frequency depends on the fund's schedule.
XBI is a US-domiciled ETF (not UCITS). Non-US investors should consider the US estate tax implications (40% on US assets above $60,000) and the 30% dividend withholding tax (reduced by treaty in some countries).
XBI uses full physical replication, meaning it holds all (or nearly all) securities in the S&P Biotechnology Select Industry Index index directly.